Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan ...

Omeros reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. This multicenter, double-blind, ...

As we age, our eyesight can change, including our ability to see things clearly both up close and at a distance. For many of ...

-- Submission of New Drug Application Planned for First Half of 2013-- -- Company to Host Conference Call Today at 9:00 a.m. EST-- SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: ...

Please provide your email address to receive an email when new articles are posted on . A novel intraocular ring provides good centration and stable holding of IOLs in the capsular bag, while ...

Omeros announced that the company submitted a New Drug Application (NDA) to the FDA for approval of OMS302 for use in patients undergoing intraocular lens replacement (ILR) surgery. OMS302, added to ...

There is a small risk of needing further surgical treatment (such as IOL replacement implanted by a different one or surgery to improve vision) after the implantation of the initial IOL. A toric IOL ...

enVista Envy full range of vision intraocular lens (IOL) met all primary efficacy and safety endpoints in multicenter study Results show that enVista Envy IOLs deliver excellent visual performance, ...

SEATTLE, Jan. 22, 2013 /PRNewswire/ – Omeros Corporation (OMER) today announced the successful completion of the 90-day safety database lock in the second of the Company's two pivotal Phase 3 clinical ...

TORONTO, Feb. 1, 2021 /CNW/ - Alcon, the global leader in eye care, is pleased to announce a nationwide launch of the Clareon ® intraocular lens (IOL) with the AutonoMe ® delivery system in Canada.

RxSight reported preliminary Q4 results, capping off a record year for growth where sales climbed by approximately 82%. The company is capturing strong demand for its adjustable intraocular lens ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE:ALC), the global leader in eye care announced AcrySof® IQ Vivity®, a first-of-its-kind intraocular lens (IOL) is now commercially available in select European ...